A Great Place to Do Great Things: Developing Game-Changing Technology at Abbott

Abbott has been named a top employer by Science, evaluated by 6,950 people in science fields around the world.

Science has spoken: Abbott (No. 10 on the DiversityInc Top 50 Companies list) is, again, among the best science-based companies to work for in the world.


For the 14th year, the journal Science today recognized Abbott on its Top Employers list, which is based on an evaluation of 23 characteristics including financial strength, easy adaptation to change, and a research-driven environment.

At Abbott, scientists develop life-changing technologies that help people live their best lives through good health. From freeing people with diabetes from routine finger sticks1, to building a cardiac device to save lives, to hunting for new virus mutations, every day Abbott employees are doing work that matters.

"Abbott's diverse businesses and product lines open up exciting career opportunities for our scientists across a range of technologies," said John Frels, Ph.D., chair of Abbott's Scientific Governing Board, which oversees the company's senior scientific career track.

"We strive to foster a culture of innovation and collaboration within our teams and in our work with others to gain fresh perspectives and further inspire our scientists to continue to push the boundaries on scientific advancements. This contributes to a strong, vibrant and fulfilling environment for scientists to develop their careers – and supports Abbott's long, successful legacy of scientific achievement and game-changing technology."

Our spirit of innovation and relentless focus on pushing the frontiers of science have allowed our company to thrive for more than 125 years. Today, we're working tirelessly to carry on that great legacy and to address some of healthcare's greatest challenges.

Some of Abbott's latest breakthroughs include:

  • A unified family of innovative next-generation diagnostics systems across lab disciplines that offer more efficiency, flexibility and confidence to health systems, and better help doctors and nurses get the results they need to improve decision-making and patient care.
  • Our revolutionary diabetes technology that replaces blood glucose monitoring, freeing people with diabetes from the pain and hassles of routine fingersticks.
  • Pioneering neuromodulation technology that can transform quality of life for many people who are otherwise unable to find relief from their chronic pain, while also reducing or stabilizing opioid use among patients battling chronic pain conditions.
  • first-of-its-kind cardiac device that has transformed the treatment of certain kinds of mitral regurgitation (MR) for people who are too frail for open-heart surgery or those who are not candidates for surgery.
  • Groundbreaking research that has helped bring infant formula closer than ever to breast milk.

Learn more about career opportunities at Abbott

ABOUT THE 2017 SCIENCE SURVEY

The 2017 Science survey sought to identify the companies with the best reputations as employers. The findings are based on 6,950 completed surveys from readers of Science and other survey invitees. Survey respondents came from North America (65%), Europe (25%) and Asia/Pacific Rim (7%); 94% work in biotechnology, biopharmaceutical and pharmaceutical companies. Here's a complete list of the rankings, which also are available in the Oct. 20, 2017 print edition of Science.

1 A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycaemia or impending hypoglycaemia is reported by the system or when symptoms do not match the system readings.

Abbott: Connected Devices Turn Data Into Better Health

Abbott's Robert Ford Joins a Panel Discussing the Potential for Connected Medical Devices to Improve Patient Care and Drive Better Outcomes.

Originally Published by Abbott.

Today's medical devices are creating terabytes of information that gives patients, doctors and health providers real-time insight into someone's vital statistics, heart health and even bloodwork.

But can all this new information really make someone healthier?

Read More Show Less

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

State-of-the-art multi-assay test system helps people with diabetes get the HbA1c results they need within three minutes — allowing more time for consultation and care during a single healthcare visit.

Originally Published by Abbott.

Abbott announced the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

Read More Show Less

Abbott's Xience Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan.

Originally Published by Abbott.

Abbott announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.

XIENCE Sierra was designed to help doctors more easily treat people with difficult-to-treat blockages that involve multiple or totally blocked arteries or complications such as diabetes. Complex cases are increasingly prevalent as people with coronary artery disease are living longer.

"Extensive clinical data and 10 years of real-world experience with the XIENCE family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available," said Chuck Brynelsen, senior vice president of Abbott's vascular business. "National reimbursement of XIENCE Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives."

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan. National reimbursement in Japan will enable doctors to treat more patients with XIENCE Sierra through the country's health insurance plans. XIENCE Sierra was approved in Japan on April 4, 2018, received CE Mark in Europe late last year, and is under review with the U.S. Food and Drug Administration.

XIENCE has been studied in over 100 clinical trials and in 10 years of global real-world experience. Its safety profile is unprecedented with consistent low rates of stent thrombosis, even in complex cases. More than eight million people worldwide have received a XIENCE stent since its initial regulatory approval.